Evoke Pharma Inc reports results for the quarter ended in January - Earnings Summary

Evoke Pharma

14/05/2024 22:34

* Evoke Pharma Inc  EVOK.OQ  reported a quarterly adjusted
loss
of 17 cents​​ per share for the quarter ended in January, higher
than the same quarter last year, when the company reported EPS
of -67 cents.  The lone analyst forecast for the quarter was
for a loss of 21 cents per share. 
    * Revenue rose 114.3% to $1.74 million from a year ago;
analysts
expected $2.14 million. 
    * The company reported a quarterly loss of $1.58 million.
    * Evoke Pharma Inc shares had fallen by 22.8% this
quarter and
lost 55.2% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Evoke Pharma Inc
is $7.00 
This summary was machine generated from LSEG data May 14 at
09:34 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.21          -0.17          Beat
 Dec. 31 2023      -0.50          -0.59          Missed
 Sep. 30 2023      -0.62          -0.51          Beat
 Jun. 30 2023      -0.73          -0.56          Beat